245 related articles for article (PubMed ID: 36716212)
1. Empagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in routine care in East Asia: Results from the EMPRISE study.
Kim DJ; Sheu WH; Chung WJ; Yabe D; Ha KH; Nangaku M; Tan EC; Node K; Yasui A; Lei W; Lee S; Saarelainen L; Deruaz-Luyet A; Kyaw MH; Seino Y;
J Diabetes Investig; 2023 Mar; 14(3):417-428. PubMed ID: 36716212
[TBL] [Abstract][Full Text] [Related]
2. Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia.
Vistisen D; Carstensen B; Elisabetta P; Lanzinger S; Tan EC; Yabe D; Kim DJ; Sheu WH; Melzer-Cohen C; Holl RW; Núñez J; Ha KH; Halvorsen S; Langslet G; Karasik A; Nyström T; Niskanen L; Guleria S; Klement R; Carrasco M; Foersch J; Shay C; Koeneman L; Hoti F; Farsani SF; Khunti K; Zaccardi F; Subramanian A; Nirantharakumar K; ;
Cardiovasc Diabetol; 2023 Aug; 22(1):233. PubMed ID: 37653496
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of empagliflozin: final results from the EMPRISE study.
Htoo PT; Tesfaye H; Schneeweiss S; Wexler DJ; Everett BM; Glynn RJ; Schmedt N; Koeneman L; Déruaz-Luyet A; Paik JM; Patorno E
Diabetologia; 2024 Jul; 67(7):1328-1342. PubMed ID: 38509341
[TBL] [Abstract][Full Text] [Related]
4. Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.
Karasik A; Lanzinger S; Chia-Hui Tan E; Yabe D; Kim DJ; Sheu WH; Melzer-Cohen C; Holl RW; Ha KH; Khunti K; Zaccardi F; Subramanian A; Nirantharakumar K; Nyström T; Niskanen L; Linnemann Jensen M; Hoti F; Klement R; Déruaz-Luyet A; Kyaw MH; Koeneman L; Vistisen D; Carstensen B; Halvorsen S; Langslet G; Fazeli Farsani S; Patorno E; Núñez J;
Diabetes Metab; 2023 Mar; 49(2):101418. PubMed ID: 36608816
[TBL] [Abstract][Full Text] [Related]
5. Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study.
Sütő G; Molnár GA; Rokszin G; Fábián I; Kiss Z; Szekanecz Z; Poór G; Jermendy G; Kempler P; Wittmann I
BMJ Open Diabetes Res Care; 2021 Jan; 9(1):. PubMed ID: 33472796
[TBL] [Abstract][Full Text] [Related]
6. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
Patorno E; Pawar A; Franklin JM; Najafzadeh M; Déruaz-Luyet A; Brodovicz KG; Sambevski S; Bessette LG; Santiago Ortiz AJ; Kulldorff M; Schneeweiss S
Circulation; 2019 Jun; 139(25):2822-2830. PubMed ID: 30955357
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials.
Lin DS; Lee JK; Hung CS; Chen WJ
Diabetologia; 2021 Dec; 64(12):2676-2686. PubMed ID: 34536085
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study.
Seino Y; Kim DJ; Yabe D; Tan EC; Chung WJ; Ha KH; Nangaku M; Node K; Klement R; Yasui A; Lei WY; Lee S; Kyaw MH; Deruaz-Luyet A; Brodovicz KG; H-H Sheu W;
Endocrinol Diabetes Metab; 2021 Jan; 4(1):e00183. PubMed ID: 33532619
[TBL] [Abstract][Full Text] [Related]
9. Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase-4 inhibitors: Real world evidence from the Nordic EMPRISE study.
Nyström T; Toresson Grip E; Gunnarsson J; Casajust P; Karlsdotter K; Skogsberg J; Ustyugova A;
Diabetes Obes Metab; 2023 Jan; 25(1):261-271. PubMed ID: 36097728
[TBL] [Abstract][Full Text] [Related]
10. Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA1c Levels.
D'Andrea E; Wexler DJ; Kim SC; Paik JM; Alt E; Patorno E
JAMA Intern Med; 2023 Mar; 183(3):242-254. PubMed ID: 36745425
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.
Patorno E; Pawar A; Wexler DJ; Glynn RJ; Bessette LG; Paik JM; Najafzadeh M; Brodovicz KG; Déruaz-Luyet A; Schneeweiss S
Diabetes Obes Metab; 2022 Mar; 24(3):442-454. PubMed ID: 34729891
[TBL] [Abstract][Full Text] [Related]
12. Healthcare resource utilization in patients treated with empagliflozin in East Asia.
Sheu WH; Seino Y; Tan EC; Yabe D; Ha KH; Nangaku M; Chung WJ; Node K; Yasui A; Lei WY; Lee S; Ustyugova A; Klement R; Deruaz-Luyet A; Kyaw MH; Kim DJ;
J Diabetes Investig; 2022 May; 13(5):810-821. PubMed ID: 34859609
[TBL] [Abstract][Full Text] [Related]
13. Obesity as a modifier of the cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes.
Suissa K; Schneeweiss S; Douros A; Yin H; Patorno E; Azoulay L
Diabetes Res Clin Pract; 2022 Oct; 192():110094. PubMed ID: 36167266
[TBL] [Abstract][Full Text] [Related]
14. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias?
Suissa S
Diabetes Care; 2018 Jan; 41(1):6-10. PubMed ID: 29263192
[TBL] [Abstract][Full Text] [Related]
15. Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: A nationwide cohort study.
Huang TL; Hsiao FY; Chiang CK; Shen LJ; Huang CF
PLoS One; 2019; 14(5):e0215248. PubMed ID: 31112536
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
Scheen AJ
Circ Res; 2018 May; 122(10):1439-1459. PubMed ID: 29748368
[TBL] [Abstract][Full Text] [Related]
17. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ
Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543
[TBL] [Abstract][Full Text] [Related]
18. Comparison of SGLT2 inhibitors with DPP-4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus.
Lyu YS; Oh S; Kim JH; Kim SY; Jeong MH
Cardiovasc Diabetol; 2023 Jul; 22(1):185. PubMed ID: 37481509
[TBL] [Abstract][Full Text] [Related]
19. Health care utilization and costs associated with switching from DPP-4i to GLP-1RA or SGLT2i: an observational cohort study.
Newman TV; Munshi KD; Neilson LM; Good CB; Swart ECS; Huang Y; Henderson R; Parekh N
J Manag Care Spec Pharm; 2021 Apr; 27(4):435-443. PubMed ID: 33769857
[No Abstract] [Full Text] [Related]
20. Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study.
Birkeland KI; Bodegard J; Banerjee A; Kim DJ; Norhammar A; Eriksson JW; Thuresson M; Okami S; Ha KH; Kossack N; Mamza JB; Zhang R; Yajima T; Komuro I; Kadowaki T
Diabetes Obes Metab; 2021 Jan; 23(1):75-85. PubMed ID: 32893440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
